Literature DB >> 14665508

The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock.

Frank M P van Haren1, Frans W Rozendaal, Johannes G van der Hoeven.   

Abstract

OBJECTIVE: To study the effect of continuous infusion of vasopressin on the splanchnic circulation in patients with severe septic shock.
DESIGN: Prospective clinical study.
SETTING: ICU in a teaching hospital. PATIENTS: Eleven consecutive patients with documented septic shock who remained hypotensive despite norepinephrine infusion at a rate > or =0.2 microg/kg/min.
INTERVENTIONS: Insertion of a gastric tonometry catheter, and continuous infusion of vasopressin 0.04 U/min during 4 h.
MEASUREMENTS AND MAIN RESULTS: Difference between gastric and arterial CO(2) partial pressure (P[g-a]CO(2) gap), mean arterial pressure, and cardiac index were recorded at baseline and after 15 min, 30 min, 60 min, 120 min, and 240 min. RESULTS: The median P(g-a)CO(2) gap increased from 5 mm Hg at baseline to 19 mm Hg after 4 h (p = 0.022). Mean arterial pressure increased from 61 +/- 13 mm Hg at baseline to 68 +/- 9 mm Hg after 4 h (p = 0.055). No significant changes in cardiac index were noted.
CONCLUSIONS: In norepinephrine-dependent patients in septic shock, continuous infusion of low-dose vasopressin results in a significant increase of the P(g-a)CO(2) gap compatible with GI hypoperfusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665508     DOI: 10.1378/chest.124.6.2256

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  Vasopressin and splanchnic blood flow: vasoconstriction does not equal vasoconstriction in every organ.

Authors:  P Asfar; P Radermacher; B Hauser
Journal:  Intensive Care Med       Date:  2005-11-18       Impact factor: 17.440

2.  Arginine-vasopressin in neonates with vasodilatory shock after cardiopulmonary bypass.

Authors:  Evelyn Lechner; Anna Hofer; Rudolf Mair; Werner Moosbauer; Eva Sames-Dolzer; Gerald Tulzer
Journal:  Eur J Pediatr       Date:  2007-01-16       Impact factor: 3.183

Review 3.  A global perspective on vasoactive agents in shock.

Authors:  Djillali Annane; Lamia Ouanes-Besbes; Daniel de Backer; Bin DU; Anthony C Gordon; Glenn Hernández; Keith M Olsen; Tiffany M Osborn; Sandra Peake; James A Russell; Sergio Zanotti Cavazzoni
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

4.  Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.

Authors:  François Lauzier; Bruno Lévy; Patrice Lamarre; Olivier Lesur
Journal:  Intensive Care Med       Date:  2006-09-22       Impact factor: 17.440

Review 5.  [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].

Authors:  C Ertmer; A W Sielenkämper; H van Aken; H-G Bone; M Westphal
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

Review 6.  The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients.

Authors:  E Christiaan Boerma; Can Ince
Journal:  Intensive Care Med       Date:  2010-09-02       Impact factor: 17.440

7.  Current place of vasopressin analogues in the treatment of septic shock.

Authors:  Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Martin Westphal
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

Review 8.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

Review 9.  [Sepsis therapy: present guidelines and their application].

Authors:  F M Brunkhorst; K Reinhart
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

10.  [Role of vasopressin in septic shock : critical evaluation].

Authors:  I Gradwohl-Matis; A Brunauer; D Dankl; M Dünser
Journal:  Anaesthesist       Date:  2014-06       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.